{
  "docId": "019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "docSlug": "0f1a880702ed9ddf7f6316bb24fc6717",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 37,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide outlines a clinical trial protocol, specifically a randomized open-label study comparing an experimental arm to an active comparator arm.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-d25f-763f-9eab-9ec8cb3a6b5e/16",
  "deckHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e",
  "deckJsonHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e.json",
  "deckAnchorHref": "/decks/019de076-d25f-763f-9eab-9ec8cb3a6b5e#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.78
      },
      "kind": "callout",
      "text": "A platinum resensitizing agent is a long-standing desirable and highly demanded mechanism of action of Gyn-Oncs, their so-called \"Holy Grail\".*",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bef032-9645-404f-9088-412265164475",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.29,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "Multi-center, randomized open-label n=186. Experimental Arm: Olvi-Vec + Platinum-doublet + Bevacizumab. Active Comparator Arm: Platinum-doublet + Bevacizumab.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90e436d0-4808-417c-99e4-52cd215724e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.26,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: High-grade serous, endometrioid, or clear-cell ovarian cancer; Platinum-resistant or -refractory disease; Received prior bevacizumab; Received min 3 prior lines of therapy; ECOG 0 or 1.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5edd7df-e810-4862-8673-dec08163ef21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the tumor microenvironment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f2e4270-6144-4449-9e6f-6d6919c7a29a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.73,
        "y": 0.29
      },
      "kind": "table",
      "text": "Primary Endpoint: Progression-Free Survival. Key Secondary Endpoints: AEs, DOR, ORR, OS.",
      "attrs": null,
      "subkind": "kpi",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89e3a543-99c9-4276-a8ea-d530ae2fa1b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2702eb1-d5ea-4cfc-bac3-4176205fb32a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Hypothesis-Driven Structure",
      "slug": "hypothesis-driven-structure",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "734cfd2d-ffb6-4467-8a44-4d9d2b064929",
      "evidence": "The slide outlines a Phase 3 pivotal trial design based on Phase 2 results.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}